Merck's Ezetimibe Faces Reimbursement Threat In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from the ENHANCE and ARBITER 6-HALTS trials may finally mean reduced coverage in Germany and the U.K.
You may also be interested in...
European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.
Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?
A positive outcome in the SHARP study is good news for Merck, but questions still remain about the efficacy of Vytorin compared to older statins.